Table 5.
Cox regression analysis for 5-year disease-free survival
| Variable | Category | Univariate |
Multivariate |
||
|---|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | ||
| Age (yr) | < 65 vs. ≥ 65 | 1.086 (0.669–1.765) | 0.738 | ||
| Sex | Male vs. female | 1.043 (0.601–1.808) | 0.881 | ||
| Stage | 0, I, II vs. III | 2.225 (1.360–3.640) | 0.001 | 2.177 (1.319–3.595) | 0.002 |
| pCR | Yes vs. No | 1.114 (0.619–2.008) | 0.718 | ||
| Albumin (g/dL) | < 3.5 vs. ≥ 3.5 | 0.889 (0.284–2.057) | 0.783 | ||
| Platelet (× 109/L) | < 300 vs. ≥ 300 | 1.320 (0.818–2.132) | 0.256 | ||
| PLR | < 170 vs. ≥ 170 | 1.451 (0.898–2.346) | 0.129 | ||
| NLR | < 2.8 vs. ≥ 2.8 | 1.396 (0.859–2.269) | 0.178 | ||
| Pre-CRT CEA (ng/mL) | < 5 vs. ≥ 5 | 1.749 (1.082–2.826) | 0.022 | ||
| Post-CRT CEA (ng/mL) | < 5 vs. ≥ 5 | 3.500 (2.006–6.109) | < 0.001 | 3.291 (1.853–5.845) | < 0.001 |
HR, hazard ratio; CI, confidence interval; pCR, pathologic complete response; PLR, plate-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; CRT, chemoradiotherapy; CEA, carcinoembryonic antigen.